Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial

Chit Moy Ley; Qing Ni; Xing Liao; Huai-lin Gao; Nicola Robinson

doi:10.1007/s11655-016-2521-2

Your Location：

Home >

Browse articles >

Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial

OriginalPaper | Updated：2021-08-27

- Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial
- Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial
- 中国结合医学杂志（英文版） 2016年22卷第10期页码：728-737
- Affiliations：
  
  1. School of Health and Social Care, London South Bank University,London,UK
  2. Department of Endocrinology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences,Beijing,China
  3. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences,Beijing,China
  4. Department of Endocrinology, Yiling Hospital Affiliated to Hebei Medical University,Hebei Province,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-016-2521-2
  中图分类号：
- 纸质出版日期：2016，
  
  网络出版日期：2016-7-13，
Scan for full text
Ley, C.M., Ni, Q., Liao, X. et al. Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial., Chin. J. Integr. Med. 22, 728–737 (2016). https://doi.org/10.1007/s11655-016-2521-2

Chit Moy Ley, Qing Ni, Xing Liao, et al. Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial[J]. Chinese Journal of Integrative Medicine, 2016,22(10):728-737.
Ley, C.M., Ni, Q., Liao, X. et al. Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial., Chin. J. Integr. Med. 22, 728–737 (2016). https://doi.org/10.1007/s11655-016-2521-2 DOI：

Chit Moy Ley, Qing Ni, Xing Liao, et al. Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial[J]. Chinese Journal of Integrative Medicine, 2016,22(10):728-737. DOI： 10.1007/s11655-016-2521-2.

摘要

To assess whether the dietary supplement (bromelain) has the potential to reduce plasma fibrinogen and other cardiovascular disease (CVD) risk factors in patients with diabetes. This randomized placebo controlled

double blind

parallel design

efficacy study was carried out in China and investigated the effect of 12 weeks of bromelain (1

050 mg/day) on plasma fibrinogen. This randomized controlled trial (RCT) recruited 68 Chinese diabetic patients [32 males and 36 females; Han origin

mean age of 61.26 years (standard deviation (SD)

12.62 years)] with at least one CVD risk factor. Patients were randomized into either bromelain or placebo group. While bromelain group received bromelain capsule

the placebo group received placebo capsule which consisted inert ingredient and has no treatment effect. Subjects were required to take 1

050 mg (3×350 mg) of either bromelain or starch-filled placebo capsules

two to be taken (2×350 mg) after breakfast and another (350 mg) after dinner

daily for 12 weeks. Plasma fibrinogen

CVD risk factors and anthropometric indicators were determined at baseline and at 12 weeks. The change in the fibrinogen level in the bromelain group at the end of the study showed a mean reduction of 0.13 g/L (standard deviation (SD) 0.86g/L) compared with the mean reduction of 0.36 g/L (SD 0.96 g/L) for the placebo group. However

there was no significant difference in the mean change in fibrinogen between the placebo and bromelain groups (mean difference=0.23g/L (SD 0.22 g/L)

=0.291). Similarly

the difference in mean change in other CVD risk factors (blood lipids

blood pressure)

blood glucose

C-reactive protein and anthropometric measures between the bromelain and placebo groups was also not statistically significant. Statistical differences in fibrinogen between bromelain and placebo groups before the trial despite randomization may have influenced the results of this study. This RCT failed to show a beneficial effect in reducing fibrinogen or influencing other selected CVD risk factors but suggests other avenues for subsequent research on bromelain.

Abstract

double blind

parallel design

efficacy study was carried out in China and investigated the effect of 12 weeks of bromelain (1

050 mg/day) on plasma fibrinogen. This randomized controlled trial (RCT) recruited 68 Chinese diabetic patients [32 males and 36 females; Han origin

mean age of 61.26 years (standard deviation (SD)

12.62 years)] with at least one CVD risk factor. Patients were randomized into either bromelain or placebo group. While bromelain group received bromelain capsule

the placebo group received placebo capsule which consisted inert ingredient and has no treatment effect. Subjects were required to take 1

050 mg (3×350 mg) of either bromelain or starch-filled placebo capsules

two to be taken (2×350 mg) after breakfast and another (350 mg) after dinner

daily for 12 weeks. Plasma fibrinogen

there was no significant difference in the mean change in fibrinogen between the placebo and bromelain groups (mean difference=0.23g/L (SD 0.22 g/L)

=0.291). Similarly

the difference in mean change in other CVD risk factors (blood lipids

blood pressure)

blood glucose

关键词

cardiovascular diseaseFibrinogendiabetesbromelainRandomized Control Trial

Keywords

cardiovascular diseaseFibrinogendiabetesbromelainRandomized Control Trial

references

American Heart Association. Cardiovascular disease & diabetes. http://www heart org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article jsp 2010; available from: URL: http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp

Chen X, Wang Y. The epidemic of diabetes and its impact on cardiovascular health in contemporary China. CVD Prev Control 2009;4:27–40.

China Centers for Disease Control and Prevention, CDC. China facts. http://www chinacdc net cn 2011;Available from: URL: http://www.chinacdc.net.cn

International Diabetes Federation. 5th edition of the diabetes atlas released on world diabetes day. http://wwwidf org/diabetesatlas/news/fifth-edition-release 2011 November 14;Available from: URL: http://www.idf.org/diabetesatlas/news/fifth-edition-release

Houston MC. Nutraceuticals, vitamins, antioxidants, and minerals in the prevention and treatment of hypertension. Progr Cardiovasc Dis 2005;47:396–449.

Handley DA, Hughes TE. Pharmacological approaches and strategies for therapeutic modulation of fibrinogen. Thrombosis Res 1997;87:1–36.

Livio M, Bertoni MP, de Gaetano G, Donati MB. Effect of bromelain on fibrinogen level, prothrombin complex factors and platelet aggregation in the rat. Drugs Expt Clin Res 1978;4:49–53.

Kelly GS. Bromelain: a literature review and discussion of its therapeutic applications. Alt Med Rev 1996;1:243–257.

China Medicine Centre. Approved Medicine Website. http:// www yaopinnet com/tools/yibao asp 2011 July 26;Available from: URL: http://www.yaopinnet.com/tools/yibao.asp

Felton GE. Fibrinolytic and antithrombotic action of bromelain may eliminate thrombosis in heart patients. Med Hypotheses 1980;6:1123–1133.

Bhattacharyya BK. Bromelain: an overview. Natl Prod Radiance 2008;7:359–363.

Taussig SJ. The mechanism of the physiological action of bromelain. Med Hypotheses 1980;6:99–104.

Fonseca V, Desouza C, Asnani S, Jialal I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocrine Rev 2004;25:153–175.

Ley CM, Tsiami A, Ni Q, Robinson N. A review of the use of bromelain in cardiovascular diseases. J Chin Integr Med 2011;9:702–710.

Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;24:340.

Brien S, Lewith G, Walker A, Hicks SM, Middleton D. Bromelain as a treatment for osteoarthritis: a review of clinical studies. Evid Based Complement Altern Med 2004;1:251–257.

Brien S, Lewith G, Walker AF, Middleton R, Prescott P, Bundy R. Bromelain as an adjunctive treatment for moderateto-severe osteoarthritis of the knee: a randomized placebocontrolled pilot study. Quart J Med 2006;99:841–850.

Chinese Diabetes Society. China guideline for type 2 diabetes. Beijing: Peking University Medical Press; 2010.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–501.

Chene G, Morlat P, Leport C, Hafner R, Dequae L, Charreau I, et al. Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. Contr Clin Trials 1998;19:233–248.

Leibovitz E, Hazanov N, Frieman A, Elly I, Govish D. Atorvastatin reduces fibrinogen levels in patients with severe hypercholesterolemia: additional evidence to support the anti-inflammatory effects of statins. IMAJ 2004;6:456–459.

Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thrombosis Vascul Biol 1997;17:1527–1531.

Lien TF, Cheng YH, Wu CP. Effects of supplemental bromelain on egg production and quality, serum and liver traits of laying hens. J Anim Sci Adv 2012;2:386–391.

Heinicke RM, VanDer Wal L, Yokohama M. Effect of Bromelain (ananas) on human platelet aggregation. Experientia 1972;28:844–845.

Dunn EJ, Ariens RAS. Fibrinogen and fibrin clot structure in diabetes. Herz 2004;29:470–479.

Ajjan R, Grant PJ. Coagulation and atherothrombotic disease. Atherosclerosis 2006;186:240–259.

Meletis CD. Cardiovascular disease: phytochemical and nutirional prevention and treatment. Altern Complement Ther 2003;9:158–162.

Klein G, Kullich W. Short-term treatment of painful osteoarthritis of the knee with oral enzymes: a randomised, double-blind study versus diclofenac. Clinl Drug Invest 2000;19:15–23.

Leipner J, Iten F, Saller R. Therapy with proteolytic enzymes in rheumatic disorders. Bio Drugs 2001;15:779–789.

Seligman B. Oral bromelain as adjuncts in the treatmetn of acute thrombophlebitis. Ann Epidemiol 1969;20:22–26.

Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000;84:149–161.

Standeven KF, Aridns RAS, Grant PJ. The molecular physiology and pathology of fibrin structure/function. Blood Rev 2005;19:275–288.

Knill-Jones RP, Pearce H, Batten J, Roger W. Comparative trial of nutrizym in chronic pancreatic insufficiency. Br Med J 1970;3:21–24.

Gutfreund AE, Taussig SJ, Morris AD. Effect of oral bromelain on blood pressure and heart rate of hypertensive patients. Hawaii Med J 1978;37:143–146.

Mackie IJ, Kitchen S, Machin SJ, Lowe GDO, on behalf of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on fibrinogen assays. Br J Haematol 2003;121:396–404.

Rosner B, ed. Fundamentals of biostatistics. 7th ed. Canada: Cengage Learning, Inc.; 2010.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Experimental study on topical treatment of diabetic skin ulcers with Yi Medicine “Yi Bu A Jie (以布阿节)” extract

Acupuncture for chronic achilles tendnopathy: A randomized controlled study

Study on the correlation of tongue manifestation with fibrinogen and neutrophil in acute cerebral infarction patients

Tongue as the window to the heart

Study on the changes of thrombosis-associated factors in patients with coronary heart disease of turbidity-phlegm blocking syndrome